OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

by Paul | 19th May 2026 | News

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO London and New...
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

by Paul | 31st January 2024 | News

London and New York, NY, January 31, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic...

Recent Posts

  • OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
  • OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
  • OKYO Pharma Announces Purchase of Shares by Director
  • OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
  • OKYO Pharma Announces Purchase of Shares by Chairman

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023